265. Lipodystrophy Clinical trials / Disease details
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02647853 (ClinicalTrials.gov) | October 2014 | 3/1/2016 | Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers | A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel | Nasolabial Folds;Lipoatrophy;Lipodystrophy | Drug: TAT4 Gel concentration A;Drug: TAT4 Gel concentration B;Drug: Placebo | Topokine Therapeutics, Inc. | NULL | Completed | 40 Years | 70 Years | Both | 16 | Phase 1 | United States |